CN109239253B - High performance liquid detection method for impurities of abacavir - Google Patents
High performance liquid detection method for impurities of abacavir Download PDFInfo
- Publication number
- CN109239253B CN109239253B CN201811109775.7A CN201811109775A CN109239253B CN 109239253 B CN109239253 B CN 109239253B CN 201811109775 A CN201811109775 A CN 201811109775A CN 109239253 B CN109239253 B CN 109239253B
- Authority
- CN
- China
- Prior art keywords
- abacavir
- acid solution
- solution
- phase
- performance liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/89—Inverse chromatography
Landscapes
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
The application discloses a high performance liquid detection method for impurities of abacavir, and the structural formula of the impurities is shown in the specification
Wherein R is alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, hydroxyalkyl, carboxyl or ester group; the method comprises the following steps: providing a sample analysis solution; injecting the sample analysis solution into a high performance liquid chromatograph for chromatographic analysis, and recording a chromatogram; wherein the chromatographic column is reversed phase chromatographic column, and the mobile phase is mixed solution of acid solution and solvent phase. Through the mode, the method and the device can improve the separation degree and accuracy of detection.
Description
Technical Field
The application relates to the technical field of drug analysis, in particular to a high performance liquid detection method for impurities of abacavir.
Background
Abacavir (ABC) is a new anti-aids drug, a new carbocyclic 2' -deoxyguanosine nucleoside drug, and has high oral bioavailability and easy infiltration into the central nervous system. Like other nucleoside reverse transcriptase inhibitors, it is an inactive prodrug that is metabolized to the active triphosphate in vivo in 4 steps and acts to inhibit Human Immunodeficiency Virus (HIV) reverse transcriptase via the following 2 pathways: [ problem ] to competitively inhibit the binding of 2' -deoxyguanosine triphosphate (dGTP), one of the DNA synthesis fragments, into a nucleic acid strand. ② the synthesis of DNA strands is effectively terminated by preventing the addition of new bases. The chemical structural formula of abacavir is as follows:
the preparation method of abacavir (formula VI) is as follows: reacting a compound of a formula II with a compound of a formula III under an alkaline condition to obtain a compound of a formula IV, adding triethyl orthoformate and ethanol hydrochloride to react, filtering to obtain (1S,4R) -4- (2-amino-6-chloro-9H-purin-9-yl) -2-cyclopentene-1-methanol hydrochloride (formula V), and reacting with cyclopropylamine to obtain abacavir (formula VI)
In the long-term research and development process, the inventor of the present application finds that in the process of preparing abacavir (VI), due to the chemical reaction equilibrium relationship, a small amount of raw materials remain, and are brought into the subsequent reaction steps, and will react with the raw materials or products in the subsequent reaction, so that many impurities are generated in the process of synthesizing abacavir, and the impurities can affect the purity of abacavir products, but some impurities are disclosed at present and have related detection control means, some impurities are not disclosed, and no good method is used for detecting and controlling the impurities, so a scientific and effective analysis method is urgently needed for detecting and controlling the impurities.
Disclosure of Invention
The technical problem mainly solved by the application is to provide a high-efficiency liquid phase detection method for impurities of abacavir, which can improve the separation degree and accuracy of detection.
In order to solve the technical problem, the application adopts a technical scheme that: provides a high performance liquid detection method of impurities of abacavir, the structural formula of the impurities is shown in the specification
Wherein R is alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, hydroxyalkyl, carboxyl or ester group; the method comprises the following steps: providing a sample analysis solution; injecting the sample analysis solution into a high performance liquid chromatograph for chromatographic analysis, and recording a chromatogram; wherein the chromatographic column is reversed phase chromatographic column, and the mobile phase is mixed solution of acid solution and solvent phase.
Wherein the solvent phase is a mixed solution of water and an organic phase; the organic phase is methanol or acetonitrile.
Wherein the volume ratio of the acid solution to the solvent phase in the mobile phase is 98: 2-2: 98; the volume ratio of water to the organic phase in the solvent phase is 5: 95-25: 75; the pH value of the mobile phase is 1.0-9.0.
The elution is carried out by adopting a gradient elution mode, wherein during the gradient elution, the volume ratio of the acid solution in the mobile phase is 95-70% within 0-20 minutes of the operation time, the volume ratio of the acid solution in the mobile phase is 70-10% within 20-35 minutes of the operation time, the volume ratio of the acid solution in the mobile phase is 10-95% within 35-35.1 minutes of the operation time, and the volume ratio of the acid solution in the mobile phase is 95-95% within 35.1-50 minutes of the operation time.
Wherein the acid solution is an aqueous solution, the volume concentration of the acid solution is 0.01-0.1%, and the acid solution is a formic acid solution, an acetic acid solution or a trifluoroacetic acid solution.
Wherein the reversed-phase chromatographic column is a phenylsilane bonded silica chromatographic column, a cyano bonded silica chromatographic column, an amino bonded silica chromatographic column, an octadecylsilane bonded silica chromatographic column or an octaalkylsilane bonded silica chromatographic column.
Wherein, the length of the reversed phase chromatographic column is 100 mm-300 mm, the inner diameter is 1 mm-10 mm, and the grain diameter is 1 μm-10 μm.
Wherein the flow rate of the mobile phase is 0.8-1.3 ml/min; the temperature of the chromatographic column is 25-50 ℃, and the detection wavelength is 205-300 nm; the running time is 30-70 min.
Wherein, the sample is dissolved by water, methanol, ethanol, acetonitrile, methanol-water mixed solution, ethanol-water mixed solution and acetonitrile-water mixed solution to prepare the sample analysis solution.
Wherein the sample is an abacavir bulk drug, an abacavir intermediate or an abacavir preparation.
The beneficial effect of this application is: different from the situation of the prior art, the application discovers a new impurity in the preparation process of abacavir and provides a high performance liquid detection method of the impurity, and the detection separation degree and the detection limit of the impurity can be improved by utilizing a reversed phase chromatographic column and eluting by using a mixed solvent of an acid solution and a solvent phase.
Drawings
Figure 1 is a mass spectrum of an abacavir impurity compound of the present application;
FIG. 2 is a nuclear magnetic hydrogen spectrum of an abacavir impurity compound of the present application;
FIG. 3 is a schematic flow diagram of a first embodiment of a method for high performance liquid phase detection of impurities of abacavir according to the present application;
FIG. 4 is a detection chromatogram of Experimental example 1 of the present application;
FIG. 5 is a detection chromatogram of Experimental example 2 of the present application;
FIG. 6 is a detection chromatogram of Experimental example 3 of the present application;
FIG. 7 is a detection chromatogram of Experimental example 4 of the present application;
FIG. 8 is a detection chromatogram of Experimental example 5 of the present application.
Detailed Description
In order to make the purpose, technical solution and effect of the present application clearer and clearer, the present application is further described in detail below with reference to the accompanying drawings and examples.
The application provides a high performance liquid detection method for impurities of abacavir, wherein a plurality of impurities can be generated in the synthesis process of abacavir, and the details are shown in table 1. Specifically, abacavir is generally prepared by:
the present inventors found that the compound of formula II and cyclopropylamine have similar primary amine reaction sites during the synthesis when the residual (1S-cis) -4-amino-2-cyclopentenyl-1-methanol (II) is carried into the intermediate (1S-4R) -4- (2-amino-6-chloro-9H-purin-9-yl) -2-cyclopentene-1-methanol hydrochloride (V), so that the compound of formula II and the compound of formula V react to generate impurities during the synthesis of abacavir, and the impurities are ((1S,4R) -4- (2-amino-6- ((1R,4S) -4- (hydroxymethyl) cyclopentyl-2-alkenylamino) -9H-purine- 9-yl) cyclopentyl-2-enyl) methanol (I), with reference to figures 1 and 2 for a detailed analysis of the results, figure 1 is a mass spectrum of an abacavir compound impurity of the present application, wherein the abscissa on the graph represents the mass to charge ratio (m/z) value of the ion; the ordinate on the graph represents the intensity of the ion flow; in the present application, compound I has a characteristic peak at 343.5m/z in the mass spectrometric assay; FIG. 2 is a nuclear magnetic hydrogen spectrum of an impurity of an abacavir compound of the present application, wherein the ordinate on the graph is the nuclear magnetic resonance peak signal intensity; the abscissa on the graph is the resonant magnetic field strength (resonant frequency); in the present application, the NMR spectrum of the above-mentioned Compound I: (1H NMR spectrum) of1H NMR(400MHzMeOD), δ 1.45 to 1.73(m, 2H), 2.60 to 2.80(m, 2H), 2.81 to 2.88(m, 1H), 2.90 to 3.09(m, 1H), 3.57 to 3.61(m, 2H), 3.63 to 3.66(m, 2H), 5.529 to 5.531(m, 1H), 5.571 to 5.591(m, 1H), 5.87 to 5.90(m, 1H), 5.91 to 5.93(m, 1H), 5.95 to 5.97(m, 1H), 6.18 to 6.20(m, 1H), 7.74(s, 1H). The compound (formula I) is not mentioned in the past literature and lacks a corresponding analysis method, but is generated in the actual production of abacavir, so that the application provides a detection method for detecting such impurities.
Table 1: abacavir impurity name and structure
Referring to fig. 3, fig. 3 is a schematic flow chart of a first embodiment of a method for high performance liquid detection of impurities in abacavir according to the present application. In this embodiment, the detection method comprises the steps of:
s301: a sample analysis solution is provided.
Wherein, when preparing the sample analysis solution, the content of impurities in the sample analysis solution should be controlled within a proper range in consideration of the detection limit, for example, the content of impurities may be 0.1-10 μ g.
Wherein the structural formula of the impurity compound is
Wherein R is alkyl, alkenyl, alkynyl, aryl, hydroxyl, halogen, hydroxyalkyl, carboxyl or ester group; in particular, the compound may be
S302: injecting the sample analysis solution into a high performance liquid chromatograph for chromatographic analysis, and recording a chromatogram; wherein the chromatographic column is a reversed phase chromatographic column, and the mobile phase is a mixed solution of an acid solution and a solvent phase.
According to the specification requirement of a chromatograph, firstly setting detection conditions, injecting sample after the instrument runs stably, eluting by using a mobile phase, recording a chromatogram, and analyzing the chromatogram to obtain the content of impurities.
In this embodiment, by using a reverse phase chromatography column and performing elution using a mixed solvent of an acid solution and a solvent phase, the separation degree and accuracy of detection of impurities can be improved.
The abacavir contains various impurities, the impurities may influence each other, and researches show that due to large polarity difference among the impurities, the other impurities do not influence the determination of the compound I (impurity M) in the abacavir, and the impurities J and L influence the determination of the compound (I) in the abacavir, so that the influence of the impurities J and L on the determination of the compound (I) in the abacavir is researched while the detection method of the compound I is developed.
In one embodiment, the detection is performed by reverse phase High Performance Liquid chromatography (RT-HPLC or RP-HPLC), which is a Liquid chromatography system consisting of a non-polar stationary phase and a polar mobile phase, and is suitable for separating non-polar, polar or ionic compounds. Therefore, the used chromatographic column is a reverse phase chromatographic column, and the reverse phase chromatographic column is selected from one or more of a phenylsilane chemically bonded silica chromatographic column, a cyano-bonded silica chromatographic column, an amino-bonded silica chromatographic column, an octadecylsilane chemically bonded silica chromatographic column or an octaalkylsilane chemically bonded silica chromatographic column.
The specific specifications of the reversed phase chromatographic column are as follows: the column length is 100mm to 300mm, such as 150mm, 200mm, 250mm and the like; an inner diameter of 1mm to 10mm, for example, 2.5mm, 5.0mm, 8.0mm, etc.; the particle size is 1 to 10 μm, for example, 2, 3, 5, 7 μm. For example, it may be a Waters symmetry C18(3.9 × 150mm,5um) octadecylsilane bonded silica chromatography column.
The mobile phase is a mixed solution of an acid solution and a solvent phase, and the solvent phase is a mixed solution of water and an organic phase; the organic phase is methanol or acetonitrile; the acid solution is formic acid solution, acetic acid solution or trifluoroacetic acid solution; the acid solution is an aqueous solution, and the volume concentration of the acid solution is 0.01% -0.1%, such as 0.03%, 0.05%, 0.08%, 0.10% and the like. For example, the acid solution is a trifluoroacetic acid-water solution of 0.05% concentration by volume. The pH value of the mobile phase is 1.0-9.0, such as pH values of 1.5, 3.5, 5.5, 6.0, 7.5, 8.5, etc.
Wherein the volume ratio of the acid solution to the solvent phase in the mobile phase is 98: 2-2: 98; such as 90:10, 70:30, 50:50, 30:70, 15:85, etc. The volume ratio of water to the organic phase in the solvent phase is 5: 95-25: 75; e.g., 10:90, 15:85, 20:80, 25:75, etc. For example, the solvent phase may be water: methanol is a 15:85 mixture.
Specifically, chromatographic conditions are set, wherein the flow rate of the mobile phase is 0.8-1.3 ml/min, such as 0.9ml/min, 1.0ml/min, 1.1ml/min, 1.2ml/min and the like; the temperature of the chromatographic column is 25-50 ℃, such as 30 ℃, 35 ℃, 40 ℃, 45 ℃ and the like; the detection wavelength of the detector is 205-300 nm, such as 225nm and 256 nm; the running time is 30-70 min.
In one embodiment, a gradient elution method is adopted for elution, specifically, during the gradient elution, the volume ratio of the acid solution in the mobile phase is 95-70% within 0-20 minutes of the operation time, the volume ratio of the acid solution in the mobile phase is 70-10% within 20-35 minutes of the operation time, the volume ratio of the acid solution in the mobile phase is 10-95% within 35-35.1 minutes of the operation time, and the volume ratio of the acid solution in the mobile phase is 95-95% within 35.1-50 minutes of the operation time.
In one embodiment, a sample is dissolved using water, methanol, ethanol, acetonitrile, a methanol-water mixture, an ethanol-water mixture, or an acetonitrile-water mixture as a solvent to prepare a sample analysis solution. Specifically, the method can also be applied to detecting impurities in the abacavir bulk drug, the abacavir intermediate or the abacavir preparation, namely in a sample analysis solution, the sample can be the abacavir bulk drug, the intermediate or the preparation, and when the sample is different, the solubility difference of the sample is utilized, and different solvents are selected for dissolving. Wherein the abacavir preparation can be tablet, capsule, granule, eye preparation, nasal preparation, suppository, pill, ointment cream, cataplasm, inhalation preparation, spray, aerosol, gel, powder, syrup, liniment, plastics, tincture, patch, oral solution, implant, membrane, lotion, rinse, decocted extract, plaster, distillate and liniment.
In the following, the scheme of the present application will be illustrated and explained by several groups of specific experimental examples, but these experimental examples are only some exemplary schemes and should not be used to limit the scope of the present application. In the experimental examples, the experimental method not specified under the specific conditions is generally performed under the conventional conditions or the conditions recommended by the manufacturer. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
Experimental example 1
(1) Instrumentation and chromatographic conditions
High performance liquid chromatograph: e2965 high-performance liquid chromatography system and workstation.
A chromatographic column: thermo Syncronis C18(4.6 mm. times.250 mm,5 μm) octadecylsilane bonded silica chromatography column.
Mobile phase: preparing a trifluoroacetic acid-water solution with the volume concentration of 0.05%, preparing a water/methanol (15/85) mixed solution, mixing the trifluoroacetic acid-water solution with the water-methanol mixed solution to prepare a mobile phase, wherein the trifluoroacetic acid solution- (water/methanol ═ 15/85) in the mobile phase is subjected to gradient elution at the time points of 0-20 min, 20-35 min, 35-35.1 min and 35.1-50 min, and the volume ratio of the acid solution is 95-70%, 70-10%, 10-95% and 95-95%.
Detection conditions are as follows: the flow rate was set at 1.0ml/min, the detection wavelength at 254nm, and the column temperature at 30 ℃.
(2) Experimental procedure
Preparation of sample analysis solutions:
predetermined amounts of a standard sample of impurity J, impurity L, compound I and abacavir, respectively, were dissolved and diluted with methanol-water (20:80) to obtain sample analysis solutions containing about 2.5. mu.g of impurity J, impurity L, compound I and 250. mu.g of abacavir per 1ml of sample analysis solution.
Testing of sample analysis solutions:
precisely measuring 20 μ l of the above analysis solution, injecting into high performance liquid chromatograph, performing gradient elution with the mobile phase, and recording chromatogram, wherein the chromatogram is shown in figure 4. Fig. 4 is a chromatogram for detection in experimental example 1 of the present application, in which the Retention Time (RT) ═ 26.541min peak is impurity J, the RT ═ 27.921min peak is compound I, the RT ═ 28.898min peak is abacavir, and the RT ═ 31.103min peak is impurity L.
According to the chromatogram, the impurity J, the impurity L, the compound I and the abacavir can be completely separated under the condition, and the content of each impurity can be accurately measured.
Experimental example 2
(1) Instrumentation and chromatographic conditions
High performance liquid chromatograph: e2965 high-performance liquid chromatography system and workstation.
A chromatographic column: waters symmetry C18 (3.9X 150mm,5um) octadecylsilane bonded silica chromatography column.
Mobile phase: preparing a trifluoroacetic acid-water solution with the volume concentration of 0.02%, preparing a water/methanol (15/85) mixed solution, mixing the trifluoroacetic acid-water solution with the water-methanol mixed solution to prepare a mobile phase, wherein the trifluoroacetic acid solution- (water/methanol ═ 15/85) in the mobile phase is subjected to gradient elution at the time points of 0-20 min, 20-35 min, 35-35.1 min and 35.1-50 min, and the acid solution is subjected to gradient elution at the volume ratios of 95-70%, 70-10%, 10-95% and 95-95%.
Detection conditions are as follows: the flow rate was set at 1.0ml/min, the detection wavelength at 254nm, and the column temperature at 30 ℃.
(2) Experimental procedure
Preparation of sample analysis solutions:
predetermined amounts of a standard sample of impurity J, impurity L, compound I and abacavir, respectively, were dissolved and diluted with methanol-water (20:80) to obtain sample analysis solutions containing about 2.5. mu.g of impurity J, impurity L, compound I and 250. mu.g of abacavir per 1ml of sample analysis solution.
Testing of sample analysis solutions:
precisely measuring 20 μ l of the above analysis solution, injecting into high performance liquid chromatograph, performing gradient elution with the mobile phase, and recording chromatogram, wherein the chromatogram is shown in figure 5. Fig. 5 is a chromatogram for detection of experimental example 2 of the present application, in which the Retention Time (RT) ═ 25.729min peak is impurity J, the RT ═ 27.036min peak is compound I, the RT ═ 27.767min peak is abacavir, and the RT ═ 29.739min peak is impurity L.
According to the chromatogram, the impurity J, the impurity L, the compound I and the abacavir can be completely separated under the condition, and the content of each impurity can be accurately measured.
Experimental example 3
(1) Instrumentation and chromatographic conditions
High performance liquid chromatograph: e2965 high-performance liquid chromatography system and workstation.
A chromatographic column: waters symmetry C18 (3.9X 150mm,5um) octadecylsilane bonded silica chromatography column.
Mobile phase: preparing a trifluoroacetic acid-water solution with the volume concentration of 0.05%, preparing a water/methanol (15/85) mixed solution, mixing the trifluoroacetic acid-water solution with the water-methanol mixed solution to prepare a mobile phase, wherein the trifluoroacetic acid solution- (water/methanol ═ 15/85) in the mobile phase is subjected to gradient elution at the time points of 0-20 min, 20-35 min, 35-35.1 min and 35.1-50 min, and the volume ratio of the acid solution is 95-70%, 70-10%, 10-95% and 95-95%.
Detection conditions are as follows: the flow rate was set at 1.0ml/min, the detection wavelength at 254nm, and the column temperature at 30 ℃.
(2) Experimental procedure
Preparation of sample analysis solutions:
predetermined amounts of a standard sample of impurity J, impurity L, compound I and abacavir, respectively, were dissolved and diluted with methanol-water (20:80) to obtain sample analysis solutions containing about 2.5. mu.g of impurity J, impurity L, compound I and 250. mu.g of abacavir per 1ml of sample analysis solution.
Testing of sample analysis solutions:
precisely measuring 20 μ l of the above analysis solution, injecting into high performance liquid chromatograph, performing gradient elution with the mobile phase, and recording chromatogram, wherein the chromatogram is shown in figure 6. Fig. 6 is a detection chromatogram of experimental example 3 of the present application, in which the Retention Time (RT) ═ 26.717min peak is impurity J, the RT ═ 28.013min peak is compound I, the RT ═ 29.022min peak is abacavir, and the RT ═ 31.033min peak is impurity L.
According to the chromatogram, the impurity J, the impurity L, the compound I and the abacavir can be completely separated under the condition, and the content of each impurity can be accurately measured.
Experimental example 4
(1) Instrumentation and chromatographic conditions
High performance liquid chromatograph: e2965 high-performance liquid chromatography system and workstation.
A chromatographic column: waters symmetry C18 (3.9X 150mm,5um) octadecylsilane bonded silica chromatography column.
Mobile phase: preparing a trifluoroacetic acid-water solution with the volume concentration of 0.05%, preparing a water/acetonitrile (15/85) mixed solution, mixing the trifluoroacetic acid-water solution with the water-acetonitrile mixed solution to prepare a mobile phase, wherein the trifluoroacetic acid solution- (water/acetonitrile ═ 15/85) in the mobile phase is subjected to gradient elution at the time points of 0-20 min, 20-35 min, 35-35.1 min and 35.1-50 min, and the acid solution is subjected to gradient elution at the volume ratios of 95-70%, 70-10%, 10-95% and 95-95%.
Detection conditions are as follows: the flow rate was set at 1.0ml/min, the detection wavelength at 254nm, and the column temperature at 30 ℃.
(2) Experimental procedure
Preparation of sample analysis solutions:
predetermined amounts of a standard sample of impurity J, impurity L, compound I and abacavir, respectively, were dissolved and diluted with methanol-water (20:80) to obtain sample analysis solutions containing about 2.5. mu.g of impurity J, impurity L, compound I and 250. mu.g of abacavir per 1ml of sample analysis solution.
Testing of sample analysis solutions:
precisely measuring 20 μ l of the above analysis solution, injecting into high performance liquid chromatograph, performing gradient elution with the mobile phase, and recording chromatogram, wherein the chromatogram is shown in figure 7. Fig. 7 is a chromatogram for detection of experimental example 4 of the present application, in which the Retention Time (RT) ═ 27.946min peak is impurity J, the RT ═ 29.372min peak is compound I, the RT ═ 30.422min peak is abacavir, and the RT ═ 32.645min peak is impurity L.
According to the chromatogram, the impurity J, the impurity L, the compound I and the abacavir can be completely separated under the condition, and the content of each impurity can be accurately measured.
Experimental example 5
(1) Instrumentation and chromatographic conditions
High performance liquid chromatograph: e2965 high-performance liquid chromatography system and workstation.
A chromatographic column: waters symmetry C18 (3.9X 150mm,5um) octadecylsilane bonded silica chromatography column.
Mobile phase: preparing a trifluoroacetic acid-water solution with the volume concentration of 0.05%, preparing a water/methanol (15/85) mixed solution, mixing the trifluoroacetic acid-water solution with the water-methanol mixed solution to prepare a mobile phase, wherein the trifluoroacetic acid solution- (water/methanol ═ 15/85) in the mobile phase is subjected to gradient elution at the time points of 0-20 min, 20-35 min, 35-35.1 min and 35.1-50 min, and the volume ratio of the acid solution is 95-70%, 70-10%, 10-95% and 95-95%.
Detection conditions are as follows: the flow rate was set at 1.0ml/min, the detection wavelength at 254nm, and the column temperature at 30 ℃.
(2) Experimental procedure
Preparation of sample analysis solutions:
predetermined amounts of a standard sample of impurity J, impurity L, compound I and abacavir, respectively, were dissolved and diluted with methanol-water (20:80) to obtain sample analysis solutions containing about 2.5. mu.g of impurity J, impurity L, compound I and 250. mu.g of abacavir per 1ml of sample analysis solution.
Testing of sample analysis solutions:
precisely measuring 20 μ l of the above analysis solution, injecting into high performance liquid chromatograph, performing gradient elution with the mobile phase, and recording chromatogram, wherein the chromatogram is shown in figure 8. Fig. 8 is a detection chromatogram of experimental example 5 of the present application, in which the Retention Time (RT) ═ 28.462min peak is impurity J, the RT ═ 29.965min peak is compound I, the RT ═ 31.030min peak is abacavir, and the RT ═ 33.422min peak is impurity L.
According to the chromatogram, the impurity J, the impurity L, the compound I and the abacavir can be completely separated under the condition, and the content of each impurity can be accurately measured.
According to the scheme, a new impurity in the preparation process of abacavir is discovered, a high performance liquid detection method of the impurity is provided, and the detection separation degree and the detection limit of the impurity can be improved by utilizing a reversed phase chromatographic column and eluting with a mixed solvent of an acid solution and a solvent phase.
The above description is only for the purpose of illustrating embodiments of the present application and is not intended to limit the scope of the present application, and all modifications of equivalent structures and equivalent processes, which are made by the contents of the specification and the drawings of the present application or are directly or indirectly applied to other related technical fields, are also included in the scope of the present application.
Claims (5)
1. The high performance liquid detection method of the impurities of the abacavir is characterized in that the structural formula of the impurities is shown as
The method comprises the following steps:
providing a sample analysis solution;
injecting the sample analysis solution into a high performance liquid chromatograph for chromatographic analysis, and recording a chromatogram; the method comprises the following steps of (1) preparing a chromatographic column, wherein the chromatographic column is a reverse phase chromatographic column, the reverse phase chromatographic column is an octadecylsilane chemically bonded silica chromatographic column, the mobile phase is a mixed solution of an acid solution and a solvent phase, and the solvent phase is a mixed solution of a water-organic phase;
the volume ratio of the acid solution to the solvent phase in the mobile phase is 98: 2-2: 98; the volume ratio of water to the organic phase in the solvent phase is 5: 95-25: 75; the pH value of the mobile phase is 1.0-9.0;
eluting by adopting a gradient elution mode, wherein during gradient elution, the volume ratio of the acid solution in the mobile phase is 95-70% within 0-20 minutes of the operation time, the volume ratio of the acid solution in the mobile phase is 70-10% within 20-35 minutes of the operation time, the volume ratio of the acid solution in the mobile phase is 10-95% within 35-35.1 minutes of the operation time, and the volume ratio of the acid solution in the mobile phase is 95-95% within 35.1-50 minutes of the operation time;
the organic phase is methanol or acetonitrile;
the sample is an abacavir bulk drug, an abacavir intermediate or an abacavir preparation.
2. The high performance liquid chromatography detection method of abacavir impurity according to claim 1,
the acid solution is an aqueous solution, the volume concentration of the acid solution is 0.01-0.1%, and the acid solution is a formic acid solution, an acetic acid solution or a trifluoroacetic acid solution.
3. The high performance liquid chromatography detection method of abacavir impurity according to claim 1,
the length of the reversed phase chromatographic column is 100 mm-300 mm, the inner diameter is 1 mm-10 mm, and the grain diameter is 1 μm-10 μm.
4. The high performance liquid chromatography detection method of abacavir impurity according to claim 1,
the flow rate of the mobile phase is 0.8-1.3 ml/min; the temperature of the chromatographic column is 25-50 ℃, and the detection wavelength is 205-300 nm; the running time is 30-70 min.
5. The high performance liquid chromatography detection method of abacavir impurity according to claim 1,
the providing a sample analysis solution comprises: and dissolving the sample by using water, methanol, ethanol, acetonitrile, methanol-water mixed liquor, ethanol-water mixed liquor and acetonitrile-water mixed liquor to prepare the sample analysis solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811109775.7A CN109239253B (en) | 2018-09-21 | 2018-09-21 | High performance liquid detection method for impurities of abacavir |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811109775.7A CN109239253B (en) | 2018-09-21 | 2018-09-21 | High performance liquid detection method for impurities of abacavir |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109239253A CN109239253A (en) | 2019-01-18 |
| CN109239253B true CN109239253B (en) | 2021-07-09 |
Family
ID=65056642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811109775.7A Active CN109239253B (en) | 2018-09-21 | 2018-09-21 | High performance liquid detection method for impurities of abacavir |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109239253B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112129878A (en) * | 2020-10-16 | 2020-12-25 | 苏州新药篮生物医药科技有限公司 | Analysis method of medical organic intermediate impurities |
| CN116298027A (en) * | 2022-12-28 | 2023-06-23 | 江苏诺泰澳赛诺生物制药股份有限公司 | Liquid chromatography detection method and application of genotoxic impurities |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY104575A (en) * | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| EP1905772A1 (en) * | 2006-09-28 | 2008-04-02 | Esteve Quimica, S.A. | Process for the preparation of abacavir |
| EP1939196A1 (en) * | 2006-12-21 | 2008-07-02 | Esteve Quimica, S.A. | Process for the preparation of abacavir |
| US10640499B2 (en) * | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CN107641122B (en) * | 2017-08-18 | 2020-06-26 | 上海现代制药海门有限公司 | Abacavir intermediate and purification method thereof |
| CN107383010A (en) * | 2017-08-18 | 2017-11-24 | 上海现代制药海门有限公司 | A kind of compound and preparation method thereof |
-
2018
- 2018-09-21 CN CN201811109775.7A patent/CN109239253B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN109239253A (en) | 2019-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109239253B (en) | High performance liquid detection method for impurities of abacavir | |
| CN101233100A (en) | An impurity of anastrozole intermediate, and uses thereof | |
| Feng et al. | An efficient and target-oriented sample enrichment method for preparative separation of minor alkaloids by pH-zone-refining counter-current chromatography | |
| CN103864646B (en) | The impurity preparation of rasagiline mesilate and the method for analysis | |
| CN108205043B (en) | Detection method of levomilnacipran intermediate related substance | |
| CN107434794B (en) | Preparation method and application of vortioxetine hydrobromide degradation product | |
| CN111983091A (en) | Separation and purification method of prilocaine oxidation impurities in compound lidocaine emulsifiable paste | |
| CN109251161B (en) | Preparation method of 2-tryptophan bisulfite | |
| CN114397375B (en) | Method for detecting related substances of arbidol hydrochloride intermediate | |
| CN107356682B (en) | HPLC method for detecting 4-benzyloxy benzylidene aniline in 4-benzyloxy benzylidene-4-fluoroaniline | |
| CN112209882A (en) | Levoornidazole impurity C and preparation method and application thereof | |
| CN110873767B (en) | Rapid detection method for dexlansoprazole synthetic intermediate and related substances thereof | |
| CN113820417A (en) | Method for separating and measuring piroxicam and impurities thereof | |
| CN108732276B (en) | High performance liquid chromatography analysis method for related substances of Mcjuxtant | |
| CN109265496A (en) | A kind of synthetic method of glucoside-containing component | |
| CN105175468A (en) | Preparation method of Regadenoson of crystal form B | |
| CN113009014B (en) | High performance liquid detection method for 2-methoxy-5-fluorouracil impurities | |
| CN111285820A (en) | Mosapride citrate related substance and preparation method thereof | |
| CN109212068A (en) | A kind of efficient liquid phase detection method of the genotoxicity impurity of Zidovudine | |
| CN113552263B (en) | Apixaban intermediate and separation detection method of mutation-causing impurities thereof | |
| CN110873761A (en) | Gas chromatography detection method for escitalopram oxalate intermediate related substances | |
| CN112661762B (en) | Preparation method of epinastine impurity A | |
| CN114295747B (en) | Analysis method of Parami Wei Qishi material and impurities | |
| EP3878849B1 (en) | Pregabalin lactam methylene dimer and preparation method therefor | |
| CN108254454B (en) | Method for measuring pentazocine related substances |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: No.1, Linjiang Avenue, Linjiang Town, Haimen District, Nantong City, Jiangsu Province, 226000 Applicant after: Jiangsu Weiqida Pharmaceutical Co., Ltd Address before: 226000, Linjiang Avenue, Linjiang Town, Haimen, Jiangsu, Nantong 1, China Applicant before: SHANGHAI SHYNDEC PHARMACEUTICAL Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhou Jie Inventor after: Ding Ping Inventor after: Chen Tingting Inventor after: Sui Dianxu Inventor after: Mao Xiaona Inventor after: Chen Ye Inventor before: Zhou Jie Inventor before: Ding Ping Inventor before: Chen Tingting |
|
| CB03 | Change of inventor or designer information |